Oncology News and Research

RSS

Oncology, meaning bulk, mass, or tumor, and the suffix ''-logy'', meaning "study of") is a branch of medicine that deals with tumors (cancer). A medical professional who practices oncology is an ''oncologist''.

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Researchers at the Lady Davis Institute for Medical Research of the Jewish General Hospital and McGill University in Montreal have discovered a previously unsuspected link between two different genetic pathways which suppress the growth of cancer tumours.

8 Jan 2010

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Pfizer Inc. (Pfizer) and Debiopharm Group™ (Debiopharm) announced today that they have entered into a co-development agreement to conduct a Phase 3 trial of tremelimumab (CP675,206), a fully human anti-CTLA4 monoclonal antibody for the treatment of patients with unresectable, Stage IV melanoma.

8 Jan 2010

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Reata Pharmaceuticals, Inc. (Reata) and Kyowa Hakko Kirin Co., Ltd. (Kyowa Hakko Kirin) announced today that they have entered into a licensing agreement that provides Kyowa Hakko Kirin with the exclusive rights to develop and commercialize Reata’s lead compound, bardoxolone methyl (bardoxolone), in Japan and other selected Asian markets.

8 Jan 2010

Springer signs agreement with ISOBM to co-publish the journal Tumor Biology

Springer, a leading publisher in the fields of science, technology and medicine, has signed an agreement with the International Society of Oncology and BioMarkers (ISOBM) to co-publish the journal Tumor Biology starting in January 2010.

8 Jan 2010

China Medicine enters into Stock Subscription Agreement with OEP

China Medicine Corporation ("China Medicine" or "the Company"), primarily a leading distributor and a developer of Western pharmaceuticals, traditional Chinese medicines ("TCM"), and other nutriceuticals today announced that it has entered into a Stock Subscription Agreement for an equity private placement (the "Subscription Agreement") with One Equity Partners ("OEP"), the global private equity investment arm of JPMorgan Chase & Co.

7 Jan 2010

Prometheus Laboratories executes $260 million senior secured credit facility

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced that it has executed a $260 million senior secured credit facility. The credit facility consists of a $210 million term loan and a $50 million revolving credit line.

7 Jan 2010

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Ceragenix Pharmaceuticals, Inc. (“Ceragenix”), a medical device company focused on infectious disease and dermatology today announced that it has entered into an exclusive distribution and supply agreement (the “Agreement”) with BioPro Pharmaceutical, Inc. (“BioPro”), to commercialize EpiCeram®, a prescription topical cream for treating atopic dermatitis and other dry skin conditions, in Hong Kong and Taiwan (the “Territories”).

7 Jan 2010

Webinar features recent updates on meaningful use of certified EHR systems

Community oncologists, practice administrators and clinical staff interested in learning how the American Recovery and Reinvestment Act (ARRA), otherwise known as the stimulus package, can affect health care IT plans for community-based oncology practices are invited to attend a free webinar at 2 p.m. EST (11 a.m. PST) on Friday, Jan. 15, 2010. To register, visit www.MyOncologyServices.com/HIT. Registration is free, but space is limited.

From Elekta 7 Jan 2010

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

In a first-ever initiative, renowned health-care providers identify and describe how cancer treatment-related toxicities have a negative effect on quality of life from the perspective of patients and survivors.

7 Jan 2010

New guide reflects new breast cancer treatment options and authors' own personal experience

Twelve years ago, breast oncologist Dr. Marisa Weiss and her mother, Ellen Weiss, wrote the indispensable and highly acclaimed survivors' guide, Living Beyond Breast Cancer.

7 Jan 2010

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

Promising results from Phase II clinical trials and important biological advances in diagnosis and prognosis will be presented here, at the conference on Molecular Origins of Lung Cancer from Jan. 11-14, 2010. This conference is jointly sponsored by the AACR and the International Association for the Study of Lung Cancer.

7 Jan 2010

BioVex's Phase 3 melanoma study amended to include first line patients

BioVex Inc, a company developing new generation biologics for the treatment of cancer and prevention of infectious disease, announced today that the U.S. Food and Drug Administration (FDA) has agreed that BioVex's ongoing OPTiM clinical study in unresectable Stage IIIb-IV melanoma be amended to include untreated (i.e., first line) patients as well as previously treated patients as defined in the original protocol.

7 Jan 2010

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Alnylam Pharmaceuticals, Inc., a leading RNAi therapeutics company, announced today that it has received a milestone payment from its partner Roche related to initiation of pre-IND (investigational new drug application) studies for an RNAi therapeutics product candidate.

7 Jan 2010

Eisai acquires AkaRx for approximately $255 million

Eisai Inc. (Headquarters: Woodcliff Lake, New Jersey, Chairman and CEO: Hajime Shimizu, "Eisai") today announces the successful completion of its acquisition of the biopharmaceutical company, AkaRx, Inc. (Headquarters: Bridgewater, New Jersey, CEO: Robert E. Desjardins), for approximately $255 million.

6 Jan 2010

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

CytRx Corporation, a biopharmaceutical company, today announced that the Tumor Biology Center, Freiburg, Germany, plans to initiate a Phase 2 clinical trial with CytRx’s doxorubicin prodrug INNO-206 as a treatment for patients with advanced pancreatic cancer.

6 Jan 2010

Pfizer and Strides Arcolab announce new collaboration

Pfizer (NYSE: PFE) and Strides Arcolab today announced a new collaboration, wherein Pfizer will commercialize off-patent sterile injectable and oral products in the United States through its Established Products Business Unit.

6 Jan 2010

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

OncoGenex Pharmaceuticals, Inc., today announced that a randomized, controlled, investigator-sponsored Phase 2 clinical trial evaluating OGX-427 when administered as a monotherapy to patients with castrate resistant prostate cancer (CRPC) has received grant funding.

6 Jan 2010

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Sexual function in prostate cancer patients receiving external beam radiation therapy (EBRT) decreases within the first two years after treatment but then stabilizes and does not continuously decline as was previously thought, according to a study in the January 1 issue of the International Journal of Radiation Oncology*Biology*Physics, the official journal of the American Society for Radiation Oncology (ASTRO).

6 Jan 2010

Federal judge upholds key provisions of new law, gives FDA the power to regulate tobacco products

In a significant victory for public health, a federal judge in Kentucky today upheld most key provisions of the new law giving the U.S. Food and Drug Administration (FDA) the power to regulate tobacco products.

6 Jan 2010

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Dr. Anthony Tolcher, clinical director for South Texas Accelerated Research Therapeutics (START) at the START Center for Cancer Care in San Antonio, announced today that the first patient has been enrolled in a groundbreaking Phase I clinical trial of a novel combination anticancer regimen composed of two investigational compounds: MK-2206 from Merck & Co., Inc. and AZD6244 (ARRY-886*) from AstraZeneca.

6 Jan 2010

Oncology News and Research

Further Reading

Breakthrough findings could lead to new treatments for prostate, brain and skin cancers

Pfizer and Debiopharm Group enter into co-development agreement to conduct Phase 3 trial of tremelimumab

Kyowa Hakko Kirin receives exclusive rights to develop and commercialize bardoxolone methyl

Springer signs agreement with ISOBM to co-publish the journal Tumor Biology

China Medicine enters into Stock Subscription Agreement with OEP

Prometheus Laboratories executes $260 million senior secured credit facility

Ceragenix Pharmaceuticals and BioPro Pharmaceutical enter into agreement to commercialize EpiCeram

Webinar features recent updates on meaningful use of certified EHR systems

Cancer treatment-related toxicities have negative effect on quality of life, survivors' perspective

New guide reflects new breast cancer treatment options and authors' own personal experience

Conference highlights new biological advances in diagnosis and prognosis of lung cancer

BioVex's Phase 3 melanoma study amended to include first line patients

Alnylam Pharmaceuticals receives payment from Roche to initiate pre-IND studies for RNAi therapeutics

Eisai acquires AkaRx for approximately $255 million

Tumor Biology Center to initiate Phase 2 clinical trial with CytRx’s INNO-206

Pfizer and Strides Arcolab announce new collaboration

OncoGenex Pharmaceuticals receives grant funding for Phase 2 clinical trial of OGX-427

ASTRO: Sexual function does not decline in prostate cancer patients receiving EBRT

Federal judge upholds key provisions of new law, gives FDA the power to regulate tobacco products

Patient enrolled in Phase I clinical study of two investigational compounds: MK-2206 and AZD6244

Cancer Research eBook

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News